Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/3092
Registo completo
Campo DCValorIdioma
dc.contributor.authorBernardes, C-
dc.contributor.authorRusso, P-
dc.contributor.authorCarvalho, D-
dc.contributor.authorSaiote, J-
dc.contributor.authorRamos, J-
dc.date.accessioned2018-10-26T15:22:27Z-
dc.date.available2018-10-26T15:22:27Z-
dc.date.issued2018-02-
dc.identifier.citationClin J Gastroenterol. 2018 Feb;11(1):48-52.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3092-
dc.description.abstractInflammatory bowel disease is associated with an increased likelihood of developing lymphoma. However, it is still controversial if this risk may be attributed to the disease itself or rather represents an effect of immunosuppressive treatment. Although tumor necrosis factor alpha (TNFα) is a key cytokine for cancer immunosurveillance, the potential relationship between anti-TNFα agents and the pathogenesis of lymphoproliferative disorders remains unclear. Here, we describe the case of a patient with severe perianal Crohn's disease, treated with infliximab monotherapy, whose unusual presentation with acute groin pain required surgical intervention and led to the diagnosis of diffuse large B-cell lymphoma. However, 10 months after this episode, treatment with infliximab was restarted because the patient continued with refractory and disabling perianal disease. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains mild perianal Crohn's disease and persists in sustained clinical and imaging remission of the lymphoproliferative disorder.pt_PT
dc.language.isoengpt_PT
dc.publisherSpringerpt_PT
dc.rightsopenAccesspt_PT
dc.subjectAdultpt_PT
dc.subjectAnti-Inflammatory Agentspt_PT
dc.subjectCrohn Diseasept_PT
dc.subjectGastrointestinal Agentspt_PT
dc.subjectHumanspt_PT
dc.subjectInfliximabpt_PT
dc.subjectLymphoma, Large B-Cell, Diffusept_PT
dc.subjectMalept_PT
dc.subjectPrednisolonept_PT
dc.subjectTumor Necrosis Factor-alphapt_PT
dc.subjectCHLC GASpt_PT
dc.titleSafe Use of Infliximab for the Treatment of Severe Perianal Crohn's Disease After Diagnosis and Treatment of Lymphomapt_PT
dc.typearticlept_PT
dc.peerreviewedyespt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
degois.publication.firstPage48pt_PT
degois.publication.lastPage52pt_PT
degois.publication.issue1pt_PT
degois.publication.titleClinical Journal of Gastroenterologypt_PT
degois.publication.volume11pt_PT
dc.identifier.doi10.1007/s12328-017-0802-8pt_PT
Aparece nas colecções:GAS - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Clin J Gastro 2018 48.pdf1,06 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.